Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Actelion CEO Says 120 Patients Died in Lung Drug Study

Actelion Ltd., the Swiss drugmaker, said 120 people died in a clinical trial of more than 700 patients involving its experimental medicine macitentan.

The drug is “very unlikely” to show a statistically significant benefit in extending the lives of patients with pulmonary arterial hypertension, though the company is confident the trial will show patients are helped by the product, Chief Executive Officer Jean-Paul Clozel said on a conference call today.

“Hopefully if there is an effect on morbidity, we should also see a trend on mortality,” Clozel said. “No drug in pulmonary hypertension has ever been able to show any benefit on morbidity-mortality in a double-blind randomized study.”

Actelion fell 3.4 percent to 34.25 Swiss francs at 3:53 p.m. in Zurich.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.